Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33
A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.
Richard Tangthree-minute read
Molina Healthcare−1.04% — Molina Healthcare, down 1.04 percent today jumped more than 8% to $226.47 intraday on Monday, November 16, and closed up 7.5% at $225.25, ahead of Centene−1.35% — Centene, down 1.35 percent today and Elevance, after the Centers for Medicare and Medicaid Services (CMS), the federal agency that runs Medicaid, let states shield Medicaid members from work-requirement denials through June 30, 2027 12.
The people who know the company best used the bounce to sell. Director Steven Orlando sold 702 shares at $227.33 that day, on a Form 4, the SEC filing an insider must submit after a trade, with no 10b5-1 plan, the preset selling schedule that would make the timing automatic rather than chosen 4. Chief legal officer Jeff Barlow sold $1.62 million of stock on November 10 at around $203, and director Dale Wolf sold $329,792 on November 13 at about $206 56.
Two directors and the chief legal officer sold $2.1 million of Molina stock in a week
Data
| Value | |
|---|---|
| Barlow (CLO), Nov 10 | $1,620K |
| Wolf (director), Nov 13 | $329.8K |
| Orlando (director), Nov 16 | $159.6K |
The delay changes timing, not premium
The news that moved the tape is thinner than the price move. Under the guidance issued Friday, a state that opts in still assesses whether members meet work requirements but cannot deny applications or terminate coverage solely for failing them, and it must still move toward full implementation; states decide by December 11 whether to take the option 3.
That changes when members can be disenrolled, not how much premium per member Molina collects 2. Chief financial officer Mark Keim still expects work rules and twice-yearly eligibility checks to cut Molina's Medicaid membership about 6% in 2027, and the third-quarter medical cost ratio stands at 92.9%, where each 100 basis points is worth roughly $5 a share 2. A six-month reprieve is timing relief, not margin repair.
Molina's operating margin has fallen to 1% from 4.5% in two years
Data
| Operating margin | |
|---|---|
| Q2 '24 | 4.4% |
| Q3 '24 | 4.5% |
| Q4 '24 | 3.6% |
| Q1 '25 | 3.9% |
| Q2 '25 | 3.3% |
| Q3 '25 | 1.2% |
| Q4 '25 | -1.4% |
| Q1 '26 | 0.8% |
| Q2 '26 | 1.3% |
| Q3 '26 | 1% |
Four dollars of the $9.50 has to show up in February
The stock now trades around 24 times Keim's "at least $9.50" 2027 framework, which he explicitly called a framework rather than guidance, and about 43 times the $5.25 2026 adjusted earnings floor 2.
The $9.50 is built as $5.25 plus $4 of named repairs: $1.50 from bringing the new Florida CMS Kids contract to breakeven, $1.00 from exiting the general-issue Medicare Advantage product, and $1.50 from administrative leverage as premium grows toward $45 billion 2. It assumes no improvement in the Medicaid cost ratio, so every dollar of the $4 has to show up in February guidance 2. The shares also sit above the $219.53 average analyst target on a Hold rating 2, and Baupost, Seth Klarman's fund, had already trimmed its stake to about 450,000 shares from 634,000 in the third quarter, before the rally 7.
Four dollars of the $9.50 2027 framework is repairs Molina still has to earn
- 2026 adjusted EPS floor5.2556.8%
- Florida CMS Kids to breakeven1.516.2%
- Exit general-issue Medicare Advantage110.8%
- Administrative leverage on premium1.516.2%
Data
| Slice | Value | Share |
|---|---|---|
| 2026 adjusted EPS floor | 5.25 | 56.8% |
| Florida CMS Kids to breakeven | 1.5 | 16.2% |
| Exit general-issue Medicare Advantage | 1 | 10.8% |
| Administrative leverage on premium | 1.5 | 16.2% |
The filings say less than the rally story does
Barron's notes the new Democratic majority in Congress could extend the delays further; that is the outlet's speculation, not a decision anyone has made 8.
What the filings state is narrower: two directors and the chief legal officer sold within a week, one at $227.33 on the rally day itself with no preset plan, and every sale price sat at or above the consensus target 456. That does not prove anything about value, and it may be routine diversification. It does say the sellers were willing to take today's price. February guidance is where the framework gets tested: it either earns the $4 or breaks it, and a policy memo does not earn it for them 456.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.






Reader comments
0 comments